Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
CSIRO announces 300+ job cuts as part of restructure
CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...
Synchron raises $305m to advance brain–computer interfaces
Synchron's Stentrode BCI platform is billed as the world's first endovascular...
Air quality expert wins 2025 PM's Prize for Science
Distinguished Professor Lidia Morawska's work in the study of air quality provided vital...
